List view / Grid view
Within this issue are articles which investigate polyelectrolyte multilayers as drug carriers, discuss how developments in pharma impact logistics and examine how the industry can regulate heavy metals in medicinal cannabis. Other features include how use use the correct tablet tooling and trends for the CDMO sector this year.
The toxicity of crotoxin has been significantly reduced by combining it with nanostructured SBA-15 silica, used in vaccine formulations.
This whitepaper from NSF looks at the key causes of drug shortages and what we can do to stop them.
Oncology, industry-sponsored and a combination of the two, will account for the majority of clinical trials categories over the course of the coming year.
New research from PhRMA found that in the US, there are almost 600 paediatric medicines in development in over 2,000 clinical trials.
A study investigating the effectiveness of HPV vaccines has revealed that a single dose is as successful at preventing cervical cancer as multiple doses.
Researchers at Aston University and Birmingham Children’s Hospital, UK, have discovered a highly effective three-drug approach to treat Mycobacterium abscessus (M. abscessus), a notoriously drug-resistant pathogen that affects up to 13 percent of cystic fibrosis (CF) patients in the UK.
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
In a formal ceremony, the new headquarters for Novartis has been opened in White City, London, in close proximity to Imperial College London’s research campus.
The developers have announced solanezumab failed to show disease-modifying properties against dominantly inherited Alzheimer's disease (DIAD).
According to its developers, SAR442168 significantly reduced the appearance of new gadolinium (Gd)-enhancing T1-hyperintense brain lesions in the 120 trial patients.
The FDA has granted Investigational New Drug (IND) authorisation to KP1237 for the treatment of multiple myeloma using a patient's own Natural Killer cells.
Researchers using 4D printing have developed microneedles with backwards-facing barbs that they suggest could replace hypodermic needles in prolonged drug delivery or biosensing in future.
The first US in-human trial of CRISPR-Cas9-edited T cells has concluded with no ill effects and showed that nine months later the infused cells were still active against cancer.
7 February 2020 | By OSIsoft
Trustworthiness in data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development. Hear the latest findings from OSIsoft’s research in our upcoming webinar.
